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Edited by Ursula JakobThe ClpB–DnaK bichaperone system reactivates aggregated
cellular proteins and is essential for survival of bacteria, fungi,
protozoa, and plants under stress. AAA+ ATPase ClpB is a
promising target for the development of antimicrobials because
a loss of its activity is detrimental for survival of many patho-
gens and no apparent ClpB orthologs are found in metazoans.
We investigated ClpB activity in the presence of several com-
pounds that were previously described as inhibitor leads for the
human AAA+ ATPase p97, an antitumor target. We discovered
that N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ), the least
potent among the tested p97 inhibitors, binds to ClpB with a
Kd60 μM and inhibits the casein-activated, but not the basal,
ATPase activity of ClpB with an IC505 μM. The remaining
p97 ligands, which displayed a higher affinity toward p97, did
not affect the ClpB ATPase. DBeQ also interacted with DnaK
with a Kd100 μM and did not affect the DnaK ATPase but
inhibited the DnaK chaperone activity in vitro. DBeQ inhibited
the reactivation of aggregated proteins by the ClpB–DnaK
bichaperone system in vitro with an IC505 μM and sup-
pressed the growth of cultured Escherichia coli. The DBeQ-
induced loss of E. coli proliferation was exacerbated by heat
shock but was nearly eliminated in a ClpB-deficient E. coli
strain, which demonstrates a significant selectivity of DBeQ
toward ClpB in cells. Our results provide chemical validation of
ClpB as a target for developing novel antimicrobials. We
identified DBeQ as a promising lead compound for structural
optimization aimed at selective targeting of ClpB and/or DnaK.
On infection of a host, pathogens experience heat shock and
oxidative stress, and their survival depends on molecular re-
sponses to these external conditions. The pathogen stress
response has emerged as a critical mechanism for the devel-
opment of novel antimicrobials (1–3). However, no successful
inhibition of pathogen stress-response machinery has been
developed to date, mostly due to sequence conservation
among heat-shock proteins (Hsps) across different domains of
life.This article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).The Hsp100 family offers a unique opportunity for inhibitor
development among Hsps. The ATP-dependent Hsp100
chaperones are essential for the survival of bacteria (where
such proteins are called ClpB), lower eukaryotes (fungi and
protozoa), and plants under stressful conditions. Unlike other
heat-shock families, Hsp100 chaperones are not found in an-
imals or humans (4, 5). Hsp100 chaperones, in cooperation
with Hsp70 and Hsp40 (bacterial DnaK and DnaJ), are
uniquely responsible for reactivation of aggregated proteins in
microbial cells (6–8).
Hsp100 chaperones are required for invasiveness and/or in-
host survival of multiple significant bacterial and protozoan
pathogens including the ESKAPE bacteria (9–11), Mycobac-
terium tuberculosis (12, 13), Mycoplasma pneumoniae (14),
Salmonella typhimurium (15), Shigella dysenteriae (16, 17),
Porphyromonas gingivalis (18), Francisella tularensis (19),
Leptospira interrogans (20), Leishmania donovani (21), and the
tick-transmitted rickettsia Ehrlichia chaffeensis (22, 23). In the
malaria parasite Plasmodium falciparum, there are two
apparent Hsp100 isoforms and each one supports a different
essential element of Plasmodium infectivity (24–27). Thus,
inhibition of Hsp100 may suppress infectivity and survival of a
broad range of clinically relevant pathogenic microorganisms.
Unfortunately, no high-affinity Hsp100-selective inhibitors are
known.
Hsp100 chaperones are a subgroup of the AAA+ family of
ATPases associated with different cellular activities (28). Like
most AAA+ ATPases, Hsp100s form cylinder-shaped hex-
amers and use energy from ATP hydrolysis to induce
conformational rearrangements in protein substrates (29).
Hsp100-mediated reactivation of aggregates is linked to a
forced extraction of polypeptides from aggregated particles
and their subsequent unfolding by translocation through a
narrow channel at the center of the Hsp100 hexamer (30, 31).
Small-molecule inhibitors have been recently developed for
the human AAA+ ATPase, p97, a promising antitumor target
(32–34), which led to clinical evaluation and validated the
drugability of AAA+ proteins. We reasoned that inhibitors of
AAA+ ATPases distantly related to Hsp100 might serve as
prototype scaffolds for the development of Hsp100-selective
ligands. In this study, we investigated the effects of severalJ. Biol. Chem. (2021) 296 100079 1
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Figure 1. Effects of the inhibitor candidates on the ATPase activity of ClpB at 37 C. A, the ClpB ATPase activity was determined in the absence (blue)
and presence (red) of the pseudosubstrate κ-casein without (control) and with 100-μM inhibitor candidates (see Fig. S1). The average activity values from
three measurements normalized to the control are shown with SDs; *p < 0.05; ***p < 0.001. B, D, and E, the ClpB ATPase activity was measured in the
absence (blue) and presence (red) of κ-casein for wt ClpB (B), E279Q (D), and E678Q (E). C, FITC fluorescence anisotropy changes were determined on
titrating ClpB E279Q/E678Q into 100-nM FITC-casein with 5-mM ATP or ADP and with or without 80-μM DBeQ. The average values from two independent
measurements are shown with SDs. Solid lines show the results of fitting of the binding isotherm equation (see Experimental procedures), which gave the
following values for ATP with DBeQ—Kd, 78.5 nM; saturation signal, 0.11; Hill number, 1.48; r
2, 0.997 and for ATP without DBeQ—Kd, 77.3 nM; saturation
signal, 0.09; Hill number, 1.68; r2, 0.994. F, a comparison of the basal ATPase activity of wt ClpB (black) with W462F (red), W543F (blue), and the double-
mutant W462F/W543F (green). The average values from three measurements are shown with SDs. DBeQ, N2, N4-dibenzylquinazoline-2, 4-diamine.
Chemical modulation of ClpB–DnaKp97 inhibitor leads on the activity of bacterial ClpB. We
discovered that one of the known p97 inhibitors, N2,N4-
dibenzylquinazoline-2,4-diamine (DBeQ), is a promising
candidate compound for targeting Hsp100 chaperones.Results
DBeQ inhibits the casein-activated ATPase activity of ClpB
We investigated the ATPase activity of Escherichia coli ClpB
in the presence of three previously described p97 inhibitors:
DBeQ (32), its p97-optimized derivative ML240 (35), and an
alkylsulfanyl-1,2,4-triazole NMS-873 (36). We also tested two
ClpB inhibitor candidates previously identified through a high-
throughput ClpB interaction screen: C3 and C6 (37) (Fig. S1).
None of the above compounds, except C3, showed a significant
inhibition of the basal ClpB ATPase at 100 μM (Fig. 1A).
However, only C3 and DBeQ strongly inhibited the ClpB
ATPase in the presence of casein, a known pseudosubstrate of
ClpB and an activator of the ClpB ATPase (Fig. 1, A–B). We
also identified DBeQ, but not NMS-873, as a candidate ClpB
ATPase inhibitor in the presence of casein in the pilot screen
of 388 bioactive compounds (Fig. S2). We therefore focused
the following studies on DBeQ as a novel ClpB inhibitor
candidate.
The solubility of DBeQ in aqueous buffers is limited (32),
but we found that the DBeQ absorbance obeys the Beer–
Lambert law and the solution turbidity does not significantly2 J. Biol. Chem. (2021) 296 100079increase for concentrations of up to 100-μM DBeQ in the
presence of 1% dimethyl sulfoxide (DMSO) (Fig. S3). DBeQ
suppressed the ClpB ATPase in the presence of casein to the
basal level with an apparent IC50  5 μM (Fig. 1B), but did not
inhibit the ATP-dependent binding of casein to ClpB (Fig. 1C).
We introduced E-to-Q substitutions in the Walker B motif in
each of the two ATP-binding domains of ClpB (D1 and D2, see
Fig. S4) to disable ATP hydrolysis activity in each domain. Of
the two ATP-binding domains of ClpB, only the C-terminal
one (i.e., D2) showed casein-induced activation and was
affected by DBeQ (Fig. 1, D–E).
ClpB contains two Trp residues, W543 located between D1
and D2 and W462 in the coiled-coil middle domain (see
Fig. S4). Remarkably, the ClpB variants with each of the two
Trp residues substituted with Phe became sensitive to inhibi-
tion by DBeQ even in the absence of casein (Fig. 1F). The
sedimentation coefficient distributions for wt ClpB and the
Trp/Phe variants (Fig. S5) showed a dominant 13 to 15 S
molecular species, which corresponds to a hexameric ClpB in
equilibrium with monomers (38). Importantly, no shifts of the
sedimentation coefficient distribution maximum toward a
lower s20,w were observed in the presence of DBeQ (Fig. S5),
which indicates that DBeQ does not induce dissociation of the
ClpB hexamers. Overall, the different parameters tested above
showed that DBeQ directly affects ClpB but does not
compromise its structural integrity, with the basal ATPase
unaffected by DBeQ even at 45 C (Fig. S6).
Figure 2. Effects of DBeQ on the reactivation of protein aggregates mediated by ClpB and DnaK–DnaJ–GrpE (KJE). A, the activity of the thermally
aggregated firefly luciferase after 20 min of reactivation at 25 C in the presence of KJE, KJE + ClpB, or without the chaperones. The average values from
three measurements are shown with SDs; ***p < 0.001. B, the effects of DBeQ on the reactivation of aggregated luciferase in the presence of KJE (blue) or
KJE + ClpB (red). The average values from three measurements are shown with SDs. C, the activity of the aggregated glucose-6-phosphate dehydrogenase
(G6PDH) after 60 min of reactivation at 30 C in the presence of KJE, KJE + ClpB, or without the chaperones. The aggregation of G6PDH was arrested after 1
min (black bars) or 15 min (open bars) to produce two samples with a different average size of aggregates. The average values from three measurements are
shown with SDs; ***p < 0.001; **p < 0.01. D, the effects of DBeQ on the reactivation of aggregated G6PDH. G6PDH samples aggregated for 1 min were used
as substrates for KJE (blue). G6PDH samples aggregated for 15 min were used as substrates for KJE + ClpB (red). The average values from three mea-
surements are shown with SDs. The data in panels C and D were normalized to the activity levels measured in the absence of DBeQ. DBeQ, N2,
N4-dibenzylquinazoline-2, 4-diamine.
Chemical modulation of ClpB–DnaKDBeQ inhibits the aggregate-reactivation activity of
ClpB–DnaK
We tested the effect of DBeQ on the reactivation of aggre-
gates prepared from two model substrates: firefly luciferase
and bacterial glucose-6-phosphate dehydrogenase (G6PDH),
whose native activity was not affected by DBeQ (Fig. S7).
Either substrate can be reactivated by DnaK–DnaJ–GrpE
(KJE), albeit with a significantly lower efficiency than by ClpB
with KJE (Fig. 2, A and C), which allowed us to test the effect of
DBeQ on both components of the ClpB–DnaK bichaperone
system. Unexpectedly, we found that DBeQ inhibited both
ClpB-dependent and ClpB-independent reactivation of aggre-
gated luciferase with a similar IC50 value (Fig. 2B), which
suggests that the rate of luciferase reactivation is limited by the
activity of KJE. For aggregated G6PDH, however, ClpB-
dependent reactivation was inhibited by DBeQ with a
several-fold lower IC50 than ClpB-independent reactivation by
KJE alone (Fig. 2D). These results indicate that DBeQ inhibits
the activity of not only ClpB but also DnaK. However, we did
not detect inhibition of the DnaK ATPase activity by DBeQ
(Fig. S8A) or suppression of DnaK binding to a substrate-
mimicking peptide (Fig. S8B).DBeQ interacts with ClpB and DnaK
We used surface plasmon resonance (SPR) to verify a direct
interactionbetweenDBeQandClpB (Fig. 3) orDnaK(Fig. S9).The
binding isotherms for DBeQ and ClpB showed positive coopera-
tivity (Fig. 3B) with an apparent Kd 60 μMand a Hill coefficient
2.3 (Table S1). The DBeQ binding isotherms were virtually
identical forwtClpB and its 2Trp/Phe variants (Fig. 3). In contrast
to ClpB, the DBeQ interaction with DnaK was noncooperative
(Fig. S9, A–C) with an apparent Kd  100 μM (Table S1). The
above apparent binding affinity of DnaK for DBeQ should be
considered approximate, as it is close to the ligand solubility limit.
We determined that DBeQ interacted with the isolated
nucleotide-binding domain (NBD) of DnaK with a similar af-
finity as with the full-length protein (Fig. S9, D–F, Table S1).
As observed before (39), the ATPase activity of the DnaK NBD
is similar to that of the full-length DnaK (Fig. S8A). We found
that DBeQ did not inhibit the ATPase activity of the isolated
NBD of DnaK (Fig. S8A).
DBeQ suppresses the proliferation and survival of E. coli
ClpB is produced in E. coli cultured at 37 C and is strongly
upregulated during heat shock (Fig. S10). The ΔclpB strain,J. Biol. Chem. (2021) 296 100079 3
Figure 3. Surface plasmon resonance (SPR) analysis of the binding of DBeQ to wt ClpB (A-C), W462F (D-F), and W543F (G-I). A, D, and G, repre-
sentative SPR sensograms for three ClpB variants. Each solid line represents a sensogram obtained with a given DBeQ concentration; a higher DBeQ
concentration produces a higher SPR response. DBeQ binding isotherms are shown with the linear ligand concentration scale (B, E, and H) or the logarithmic
scale (C, F, and I). Shown are the averages with SDs from three repeated experiments. Solid lines in the panels B, C, E, F, H, and I represent the fits of the
cooperative binding model with the parameters listed in Table S1. DBeQ, N2, N4-dibenzylquinazoline-2, 4-diamine.
Chemical modulation of ClpB–DnaKwhich does not produce ClpB (40), does not show growth
defects at 37 C or during a mild heat shock at 45 C but
rapidly loses viability at 50 C (Fig. 4, B, D and F). DBeQ
inhibited the growth of E. coli at 37 C in a concentration-
dependent manner (Fig. 4A), but the DBeQ effects were
eliminated in the ΔclpB strain (Fig. 4B). The viability of E. coli
at 45 C (but not the ΔclpB strain) was strongly inhibited by
DBeQ (Fig. 4, C–D and Fig. 5). On expression of a ClpB–YFP
fusion protein in the ΔclpB strain (for the experiments shown
in Fig. 6), the cells’ susceptibility to DBeQ was restored and
was exacerbated at higher levels of ClpB expression (Fig. S11).
A critical role of ClpB in E. coli survival under severe stress
manifested at 50 C, as shown by a loss of viability of the ΔclpB
strain even without DBeQ (Fig. 4F). E. coli with an intact clpB
gene survived the heat shock at 50 C for several hours but lost
viability at the lowest DBeQ concentrations tested (Fig. 4E).
These experiments demonstrate that a treatment of E. coli with4 J. Biol. Chem. (2021) 296 100079DBeQ is toxic to the cells, but the DBeQ toxicity at a moderate
stress of 45 C is more severe than that caused by a loss of
ClpB in the ΔclpB strain.
To test the effects of DBeQ on the cross talk between ClpB
and DnaK, we investigated the effects of DBeQ on viability of 2
E. coli strains with defective DnaK: dnaK103, which produces a
truncated inactive DnaK that does not bind to its substrates
(41, 42), and dnaK756, in which substrate release from DnaK is
inefficient (43). We found that DBeQ suppressed viability of
dnaK103, but surprisingly, viability of dnaK756 was not
affected by DBeQ (Fig. 5).
To further explore the effects of DBeQ on the function of
ClpB in E. coli cells, we tracked the ClpB localization with
confocal fluorescence microscopy using a ClpB construct with
a C-terminally fused YFP. As demonstrated earlier (42, 44),
heat-induced aggregates of thermosensitive proteins, such as
Photinus pyralis luciferase, accumulate at the poles of E. coli
Figure 4. Effects of DBeQ on the growth and viability of E. coli and its ClpB-deficient strain. Growth of E. coli MC4100 (A) and MC4100ΔclpB (B) at 37 C
in the presence of an increasing concentration of DBeQ. Shown are the averages with SDs from three independent experiments. C–F, survival time courses
for MC4100 (C and E) and MC4100ΔclpB (D and F) at 45 C (C and D) and 50 C (E and F) in the presence of an increasing concentration of DBeQ. Shown are
representative results from 3 repeated experiments, including those in Figure 5. The legend in panel B applies also to panel A. The legend in panel D applies
also to panels C, E, and F. DBeQ, N2, N4-dibenzylquinazoline-2, 4-diamine.
Chemical modulation of ClpB–DnaKcells (Fig. S12). ClpB and DnaK colocalize with the aggregates
((44) and Fig. 6). Importantly, the absence of a functional
DnaK in the dnaK103 strain prevents ClpB from accumulating
with the aggregates (Fig. 6 and (42)), but in the presence of
DBeQ, ClpB colocalizes with the aggregates even in dnaK103
(Fig. 6). The heat shock–induced localization of ClpB at the
cellular poles in the dnaK756 strain with or without DBeQ was
indistinguishable from that in wt E. coli (Fig. S13). The results
with dnaK103 E. coli show that DBeQ affects localization of
ClpB in cells exposed to heat shock. The fluorescent foci
observed in E. coli in the presence of DBeQ are more diffuse
than those found in the absence of the ligand, an effect exac-
erbated in the dnaK103 strain (Fig. 6). Because the foci
localization was attributed to nucleoid occlusion (44), an
altered foci appearance in the presence of DBeQ may reflect a
modified size of the nucleoid-free space in cells whoseproliferation was challenged with DBeQ and/or a loss of a
functional DnaK.
Discussion
We hypothesized that small-molecule ligands of one AAA+
ATPase, p97, might also interact with another one, ClpB. We
tested three inhibitors that show an increasing potency toward
p97 (45): DBeQ (p97 IC503 μM), ML240 (p97 IC500.1 μM),
and NMS-873 (p97 IC500.02 μM). We discovered that
among the three ligands, only DBeQ, the least potent one
toward p97, affected ClpB (Fig. 1) with an apparent IC50 close
to that displayed toward p97. ML240 is a p97-optimized DBeQ
derivative, and its loss of potency toward ClpB suggests that a
structural diversity among AAA+ ATPases is sufficient to
allow discrimination between different ligands from the same
chemical family. Thus, it may be feasible to orthogonallyJ. Biol. Chem. (2021) 296 100079 5
Figure 5. Viability of E. coli strains after exposure to increasing concentrations of DBeQ at 45 C. The indicated strains of E. coli were incubated at
45 C in the presence of DBeQ or with only DMSO for the period of time indicated on the left (in hours) and then spotted on agar plates and incubated
overnight at 37 C. Each spot on the agar plates represents a viable culture after a 10-fold serial dilution (from left to right). Shown are representative results
from 3 repeated experiments. DBeQ, N2, N4-dibenzylquinazoline-2, 4-diamine. DMSO, dimethyl sulfoxide.
Chemical modulation of ClpB–DnaKmodify DBeQ and achieve an enhanced selectivity toward ClpB
with a lower potency toward p97 and the other AAA+
ATPases.
Antimicrobial activity of 2,4-diaminoquinazolines has been
reported before (46, 47), but without a clear identification of
their cellular targets. We have now shown that ClpB is the
main target of DBeQ in E. coli under both permissive condi-
tions and during heat stress (Figs. 4 and 5). It is remarkable
that the DBeQ-induced inhibition of E. coli viability depends
on production of a single protein, ClpB. Although the ΔclpB
strain does not respond to DBeQ, it becomes susceptible upon
expression of ClpB (Fig. S11), which indicates that ClpB is
required for the sensitivity of E. coli toward DBeQ. p97, the
known DBeQ target, is not produced in bacteria. Interestingly,6 J. Biol. Chem. (2021) 296 100079eukaryotic parasites, including Plasmodium and Leishmania,
produce p97 as well as ClpB. An antiparasitic activity of DBeQ
has been reported (48, 49), and it remains to be determined if
the compound’s preferred in vivo target is p97 or ClpB.
As shown by SPR, DBeQ binds to ClpB with a positive
cooperativity (Hill coefficient >2), which suggests multiple
binding sites (Fig. 3 andTable S1). Detection ofmultiple binding
sites for DBeQ is consistent with the oligomeric structure of
ClpB. The apparent IC50 for DBeQ is an order of magnitude
lower than the apparent Kd (Figs. 1–3, and Table S1), which
suggests that partial saturation of the DBeQ sites in the ClpB
hexamer is sufficient for a strong inhibition. Indeed, it has been
observed that incorporation of a single inactive subunit into a
hexameric ClpB blocks aggregate reactivation (50).
Figure 6. Localization of ClpB-YFP in E. coli. ClpB-YFP was expressed in the indicated Escherichia coli strains. The cells were grown at 30 C and then
shifted to 45 C for 30 min (see Experimental Procedures). The images show YFP fluorescence signal. Representative images from 3 independent ex-
periments are shown. The white bar in each panel corresponds to 2 μm.
Chemical modulation of ClpB–DnaKClpB-mediated reactivation of protein aggregates depends
on several molecular processes: the ClpB hexamer assembly,
ATP-dependent substrate binding, DnaK-dependent substrate
engagement, and ATP hydrolysis–dependent substrate
unfolding/translocation (4). Importantly, there is an allosteric
linkage between substrate binding and the ATPase engine of
ClpB, as demonstrated by activation of the ATPase in thepresence of substrates (7). We found that DBeQ does not
inhibit the ClpB hexamer assembly, substrate binding, or the
basal ATPase of ClpB, but it does affect the linkage between
substrate binding and the ATPase of the C-terminal D2
module (Fig. 1). Indeed, whereas substrate binding primarily
occurs at the N-terminal region of ClpB (51, 52), a partial
insertion of the substrate into the ClpB channel and its contactJ. Biol. Chem. (2021) 296 100079 7
Chemical modulation of ClpB–DnaKwith the D2 module have been observed even without ATP
hydrolysis (53). Moreover, D2 is fully responsible for the
casein-induced activation of the ClpB ATPase because the
activation is lost upon disabling D2 (Fig. 1E).
DBeQ-mediated modulation of the allostery within ClpB is
further demonstrated by the apparent uncoupling of the DBeQ
effects from substrate binding in the two Trp-to-Phe ClpB
variants (Fig. 1F). Trp462 is located within the mobile coiled-
coil domain of ClpB (Fig. S4), which controls the ATPase ac-
tivity of the ClpB hexamer (54, 55). Trp543 is located at the
interface between D1 and D2 (Fig. S4). Both Trp462 and
Trp543 side chains are exposed at the intersubunit interface
within the ClpB hexamer (Fig. S14). A similarity between the
DBeQ binding isotherms for wt ClpB and its Trp/Phe variants
(Fig. 3 and Table S1) indicates that the Trp/Phe substitutions
do not produce additional DBeQ binding sites in ClpB. Alto-
gether, the enhanced sensitivity of the Trp/Phe ClpB variants
toward DBeQ suggests that the ligand binding site(s) may be
located between the hexamer subunits and in the vicinity of
the D1–D2 junction.
We found that aggregate reactivation with the ClpB–DnaK
bichaperone system becomes inefficient in the presence of
DBeQ (Fig. 2). Because the energy generated from ATP in the
AAA+ engine is directly coupled with substrate translocation/
unfolding (56, 57), our results suggest that DBeQ affects a
linkage between the ClpB ATPase and substrate translocation
by suppressing the acceleration of ATPase in response to a
substrate, which decelerates substrate translocation and makes
its reactivation inefficient.
An unexpected result of our study is a discovery of in-
teractions between DBeQ and DnaK (Fig. S9) as well as inhi-
bition of the DnaK-mediated reactivation of protein aggregates
in vitro (Fig. 2). Unlike ClpB, DnaK is monomeric in solution
and supports noncooperative binding of DBeQ (Fig. S9,
Table S1). DBeQ binds to the NBD of DnaK (Fig. S9) but does
not inhibit its ATPase (Fig. S8A). Our results are consistent
with a recent report on the binding of amino-quinazolines
within the ATP site of Hsp70 (58) but may also indicate a
nonspecific interaction due to a predominance of hydrophobic
groups in DBeQ. Interestingly, C3 also inhibits KJE (37) as well
as ClpB and even luciferase (Fig. 1A, Fig. S7A). These results
demonstrate a challenge in designing selective inhibitors for
different families of molecular chaperones.
In vitro binding of DBeQ to DnaK notwithstanding, ClpB
appears as the main target of DBeQ in E. coli because the
compound’s effects manifest even in the absence of functional
DnaK in the dnaK103 strain but do not manifest in the ΔclpB
strain (Fig. 5). Remarkably, at 45 C, inhibition of ClpB with
DBeQ is more detrimental for bacterial survival than a lack of
ClpB in the ΔclpB strain. Thus, the phenotype of chemical
inhibition of ClpB transcends a loss of function, at least under
moderate stress.
Toxicity of ClpB in bacteria and its ortholog Hsp104 in yeast
has been observed for “hyperactive” protein variants with
mutations within the coiled-coil middle domain (55, 59, 60).
However, unlike the DBeQ-treated ClpB, the toxic hyperactive
variants display elevated ATPase and disaggregase activities.8 J. Biol. Chem. (2021) 296 100079The apparent toxic gain of function of the DBeQ-inhibited
ClpB in bacterial cells could be blamed on DBeQ-induced
aggregation of ClpB. However, we have not detected a pro-
pensity of ClpB to misfold and/or aggregate in the presence of
DBeQ in vitro (Fig. S5), which is also supported by a lack of
DBeQ effects on the basal ATPase activity of ClpB (Fig. 1 and
Fig. S6). Moreover, the survival of dnaK756 E. coli upon
treatment with DBeQ does not support a premise that the
compound’s toxicity in cells is linked to misfolding or aggre-
gation of its main target, ClpB, because, in such a case, a
viability rescue should not be expected in a strain with a
nonproductive DnaK chaperone (43).
Chaperone-deficient strains of E. coli, ΔclpB, and dnaK103
survive moderate heat stress of 45 C, thanks to other protein
quality control factors: chaperones and proteases whose highly
promiscuous and redundant activities are sufficient for main-
taining proteostasis in those strains (Fig. 5). Because DBeQ
apparently targets ClpB and no other chaperones in E. coli, the
ΔclpB strain is therefore resistant to DBeQ under moderate
stress conditions.
Physiologically, DnaK recruits ClpB to the aggregates and
hands the substrates over to ClpB for disaggregation. In wt
E. coli cells, a recruitment of ClpB to the aggregated proteins
located at the cell poles strictly depends on DnaK (42). A
striking polar localization of ClpB in dnaK103 cells in the
presence of DBeQ suggests that the compound allows ClpB to
overcome a deficiency of its recruiter cochaperone (Fig. 6).
However, ClpB interactions with protein aggregates become
nonproductive in the presence of DBeQ (Fig. 2). A nonpro-
ductive binding of ClpB to protein aggregates may become
dominant and could suppress viability of E. coli because it may
hinder access of other protein quality control factors to their
aggregated substrates and irreversibly disturb cellular proteo-
stasis. The above explanation of the DBeQ-induced phenotype
in E. coli is corroborated by an unexpected rescue of cellular
viability in the dnaK756 strain (Fig. 5). The DnaK756 variant
binds to aggregates but cannot release them (43). Apparently, a
substrate-trapping capability of DnaK756 counteracts the
nonproductive interactions of ClpB with the aggregates in the
presence of DBeQ and is sufficient to preserve cellular viability.
Thus, the apparent gain-of-function effect of DBeQ may be
due to disturbing the balance of cellular proteostasis by
stimulating nonproductive interactions of ClpB that suppress
effectiveness of the remaining chaperones. Importantly,
regardless of its exact mode of function in bacterial cells,
DBeQ is a potent and highly selective molecular probe that
targets and disrupts protein quality control in E. coli.
Molecular chaperones have not been previously explored as
targets for novel antimicrobials. In this work, we demonstrated
that the AAA+ disaggregase ClpB can be selectively targeted
with a small-molecule ligand in bacterial cells and that such a
treatment could produce a loss of bacterial viability. This result
is significant because mammalian cells do not contain ortho-
logues of ClpB (5), whereas many pathogenic microorganisms
require the ClpB activity for infectivity and survival. We have
also shown that owing to a complexity of the cellular protein
control machinery, understanding the mechanism of action of
Chemical modulation of ClpB–DnaKchemical inhibitors and the cellular phenotypes they produce
requires multiple orthogonal biochemical and biological tests,
such as those used in this study.
Experimental procedures
DNA constructs
The nucleotide sequence encoding the full-length E. coli
DnaK (residues 1–638) was amplified from plasmid
pTTQ19dnaK+ (61) using the following primers: DnaK-NcoI
(50-ATATACCATGGGTAAAATAATTGGTATCGACC-30)
and DnaK-XhoI (50-TATATCTCGAGTTTTTTGTCTTT
GACTTCTTC-30), where the engineered restriction sites are
underlined. The PCR product did not contain the dnaK
STOP codon. Subsequently, the dnaK sequence was cloned
into the NcoI/XhoI restriction site of pET28a. The STOP
codon was introduced between the dnaK coding sequence
and the C-terminal His-tag sequence in pET28a by site-
directed mutagenesis with the following primers: DnaK_
STOPf (50-GTCAAAGACAAAAAATAAGAGCACCACCA
CCACCACC-30) and DnaK_STOPr (50-GGTGGTGGTG
GTGGTGCTCTTATTTTTTGTCTTTGAC-30), where the
STOP codon is underlined. The final construct (plasmid
pET28-DnaK) was verified by DNA sequencing and was used
for production of DnaK.
The DNA sequence encoding the NBD of E. coli DnaK
(residues 1–388) was PCR-amplified from plasmid
pTTQ19dnaK+ (61) using the following primers: NBD-NcoI
(50-ATATACCATGGGTAAAATAATTGGTATCGACC-30)
and NBD-XhoI (50-TATATCTCGAGGTCTTTTACGT
CACCAGTCAGAAC-30), where the engineered restriction
sites are underlined. Subsequently, the NBD sequence was
cloned into the NcoI/XhoI restriction site of pET28a. The
construct (pET28-NBD1) was verified by DNA sequencing
and used for production of the DnaK NBD.
The plasmids pHSG575-ClpB-YFP and pBAD-YFP-
Luciferase (44) were provided by Bernd Bukau and Axel
Mogk (ZMBH, University of Heidelberg, Germany).
Proteins
E. coli ClpB and its variants E279Q, E678Q, E279Q/E678Q,
W462F, W543F, and W462F/W543F were produced as
described previously (52, 62, 63). To produce E. coli DnaK,
theE. coli strainBL21(DE3)was transformedwith pET28-DnaK.
Single transformants were used to prepare an overnight culture
in the LB media supplemented with kanamycin (50 μg/ml). On
the following day, the overnight culture was diluted 50-fold in 1 l
of LB with kanamycin (50 μg/ml). The culture was incubated at
30 C.When absorbance at 600nmreached 0.4, IPTGwas added
to the final concentration of 0.5 mM and the culture was incu-
bated for 2 h at 30 C with shaking at 200 RPM. Then, bacterial
cells were collected by centrifugation (Beckman JA-14, 3000
relative centrifugal force, 15 min, 4 C). The pellet was sus-
pended in 20ml of cold buffer KA (25-mMHepes-KOH, pH 7.6,
50-mM KCl, 2.5-mM MgCl2, 1-mM EDTA, 10-mM β-mer-
captoethanol, 5% glycerol) by vortexing. Cells were disrupted by
sonication followed by centrifugation (rotor Beckman JA-2011,500 RPM, 60 min, 4 C). The supernatant was loaded on a
Q Sepharose column (3.2 cm × 18 cm) equilibrated with buffer
KA. After washing with buffer KA (150ml), proteins were eluted
with an increasing gradient of buffer KB (25-mM Hepes-KOH,
pH 7.6, 550-mM KCl, 2.5-mM MgCl2, 1-mM EDTA, 10-mM
β-mercaptoethanol, 5% glycerol). The collected fractions,
which contained DnaK, were pooled and then diluted 10-fold in
buffer KC (50-mM Tris-HCl, pH 7.8, 1-mM EDTA, 5-mM
β-mercaptoethanol, 10% glycerol). The sample was loaded on
a DEAE-Sephacel column (3.2 × 12 cm) equilibrated with buffer
KC. After washing the columnwith 100ml of buffer KD (50mM
Tris-HCl pH 7.8, 50 mM NaCl, 1 mM EDTA, 5 mM β-mer-
captoethanol, 5% glycerol), proteins were eluted with an
increasing gradient of buffer KE (50-mM Tris-HCl, pH 7.8,
400-mM NaCl, 1-mM EDTA, 5-mM β-mercaptoethanol, 5%
glycerol). The collected fractions were concentrated with a
centrifugal filter device (10000 molecular weight cut-off,
3500 RPM, 4 C). Concentrated samples were resolved on a
Superdex 200 gel filtration column equilibrated with buffer KA.
Fractions containing DnaK with purity greater than 95% were
collected and concentrated to2mg/ml with a centrifugal filter
device. Protein concentration was determined by the Bradford
method. The aliquots of DnaK were stored at −20 C.
To produce the DnaK NBD, E. coli strain BL21(DE3) was
transformed with pET28-NBD1. Single transformants were
used to prepare overnight culture in the LB media supple-
mented with kanamycin (50 μg/ml). The overnight culture was
diluted 50-fold in 1 l of LB with kanamycin and incubated at
30C. When absorbance at 600 nm reached 0.4, IPTG was
added to the final concentration of 1 mM and the culture was
incubated for 3 h at 30 C with shaking at 200 RPM. The
bacterial cells were collected by centrifugation (Beckman
JA-14, 3000 relative centrifugal force, 15 min, 4 C). The pellet
was suspended in 20 ml of cold T10 buffer (40-mM Tris-HCl,
pH 8.0, 100 mM KCl, 10 mM imidazole) by vortexing. Cells
were disrupted by sonication. The soluble fraction was ob-
tained by centrifugation (Beckman JA-20, 11,500 RPM, 60 min,
4 C). The supernatant was loaded on a column with 5 ml of
nickel-nitrilotriacetic acid resin equilibrated with buffer T10.
The column was washed with 50 ml of buffer T20 (40-mM
Tris-HCl, pH 8.0, 100-mM KCl, 20-mM imidazole). Proteins
were eluted with buffer T250 (40-mM Tris-HCl, pH 8.0, 100-
mM KCl, 250-mM imidazole). Fractions containing the NBD
were pooled and concentrated with a centrifugal filter device
(10000 molecular weight cut-off, 3500 RPM, 4 C). The
concentrated NBD sample was resolved on a Superdex 200 gel
filtration column equilibrated with buffer B (50-mM Tris-HCl,
pH 7.5, 0.2 M KCl, 20-mM MgCl2, 10% glycerol, 1-mM
EDTA, 1-mM DTT). Fractions containing the NBD with pu-
rity greater than 95% were collected and concentrated to 5
mg/ml. Protein concentration was determined by the Bradford
method. The aliquots of the NBD were stored at −20 C.
Firefly luciferase, G6PDH from Leuconostoc mesenteroides,
DnaJ, andGrpEwereobtained asdescribedbefore (25, 52, 62, 64).
Peptide B2 and its FITC-labeled variant were obtained as
described before (65). κ-Casein and FITC–casein were obtained
from Sigma-Aldrich (St Louis, MO).J. Biol. Chem. (2021) 296 100079 9
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The following strains of E. coli were used: MC4100,
MC4100ΔclpB::kan (40), dnaK103 (41), and dnaK756 (66).
Chemicals
Candidate inhibitor compounds DBeQ, ML240, and NMS-
873 were purchased from Sigma-Aldrich (St Louis, MO) and
used directly without further purification; C3 and C6 were
obtained from TimTec (Newark, DE). The compounds in a
powder form were dissolved in DMSO at 10 mM and used in
biochemical studies after further dilutions.
ATPase activity assays
To determine the ATPase activity, ClpB was diluted to 28
μg/ml (49-nM hexamer) in buffer C (50-mM Tris-HCl, pH 7.4,
20-mM MgCl2, 1-mM EDTA, 0.5-mM tris(2-carboxyethyl)
phosphine [TCEP]). In some experiments, the ClpB solution
was supplemented with 17.4 μg/ml (10 μM) κ-casein. The
ClpB aliquots (18 μl) were mixed with 1 μl of the investigated
compounds at different concentrations in 100% DMSO or with
DMSO as a control. A sample without ClpB was used as a
baseline control. After a 10-min preincubation at 37 or 45 C,
the ATP hydrolysis reaction was initiated by adding 1 μl of
100-mM ATP. The samples were incubated for 60 min (basal
ClpB activity in the absence of κ-casein) or 15 min (in the
presence of κ-casein) at 37 C or 30 min at 45 C in the
absence of casein. For the E678Q ClpB variant, the incubation
time in the presence of κ-casein was 60 min. After incubation,
15 μl of each sample was mixed with 200 μl of the ammonium
molybdate/malachite green reagent (67) dispensed into a 96-
well plate, followed by an addition of 30 μl of 34% sodium
citrate (68). The plate was agitated inside a Synergy H1 reader
(BioTek, Winooski, VT) for 15 min at room temperature, and
the samples’ absorbance was measured at 630 nm. The read-
outs for ClpB-containing samples were corrected for absor-
bance of samples without ClpB, to account for nonenzymatic
production of inorganic phosphate. A standard curve obtained
with different inorganic phosphate concentrations was used to
determine the amount of phosphate produced from ATP in
the presence of ClpB.
To determine the ATPase activity of DnaK, 18 μl of DnaK
solution or DnaK NBD solution prepared in buffer C was
mixed with 1 μl of the investigated compounds or DMSO as a
control. Samples without DnaK were used as control blanks.
The samples were preincubated for 10 min at 37 C. The re-
action was initiated by adding 1 μl of 100-mM ATP bringing
the final concentration of DnaK to 1.1 μM or DnaK NBD to 3.4
μM. The samples were incubated at 37 C for 70 min for DnaK
or 75 min for NBD. The concentration of inorganic phosphate
produced from ATP in the presence of DnaK was determined
as described above for ClpB.
Aggregate reactivation assays
G6PDH was chemically denatured by mixing 5 μl of the
G6PDH stock solution (441 μM) with 5 μl of buffer A (10 M
urea, 16% glycerol, 40-mM DTT) preheated at 47 C. The10 J. Biol. Chem. (2021) 296 100079samples of G6PDH in buffer A were incubated for 5 min at
47 C. Subsequently, 5 μl of denatured G6PDH was mixed with
95 μl of buffer B (50-mM Tris-HCl, pH 7.4, 20-mMMg(OAc)2,
30-mM KCl, 1-mM EDTA, 1-mM β-mercaptoethanol) pre-
heated at 47 C to initiate protein refolding, which, under these
conditions, is inefficient and leads to misfolding and aggrega-
tion of G6PDH (69). G6PDH aggregate production was
arrested after 1 min (for refolding by KJE) or 15 min (for
refolding by KJE with ClpB) by transferring into ice for 2 min.
To observe the aggregate reactivation, aggregated G6PDH was
diluted 10-fold in buffer C (50-mM Tris-HCl, pH 7.4, 20-mM
MgCl2, 1-mM EDTA, 0.5-mM TCEP) containing the chaper-
ones KJE (5.5-μM DnaK, 1.1-μM DnaJ, 1.1-μM GrpE) or KJE-
ClpB (5.5-μM DnaK, 1.1-μM DnaJ, 1.1-μM GrpE, 1.65-μM
ClpB (hexamer)). G6PDH in buffer C without chaperones was
used as a control for a spontaneous aggregate reactivation. The
chaperone-G6PDH samples (18 μl) were supplemented with 1
μl of DBeQ in DMSO or pure DMSO as a control. The sam-
ples were incubated for 2 min at 30 C. The aggregate reac-
tivation was initiated by adding 1 μl of 100-mM ATP, followed
by incubation for 60 min at 30 C. To determine the enzymatic
activity of G6PDH, a 5-μl aliquot from the reactivated sample
was mixed with 195 μl of buffer D (50-mM Tris-HCl, pH 7.8,
5-mM MgCl2, 2-mM glucose-6-phosphate, 1-mM NADP
+) in
a 96-well plate that had been preheated at 30 C. The plate was
inserted into Synergy H1 plate reader (BioTek, Winooski, VT)
with the chamber temperature at 30 C, and the sample
absorbance at 340 nm was measured after 10 min. The amount
of NADPH produced was calculated based on the NADPH
molar extinction coefficient, Ɛ340 = 6220 [M−1 , cm−1].
Firefly luciferase (220 μM) was diluted 300-fold in PBS
buffer with 1 mg/ml bovine serum albumin and then incubated
for 12 min at 45 C. The chaperone solutions were prepared in
buffer C (50-mM Tris-HCl, pH 7.4, 20-mM MgCl2, 1-mM
EDTA, 0.5-mM TCEP): KJE (1.15-μM DnaK, 1.15-μM DnaJ,
0.57-μM GrpE) and KJE-ClpB (1.15-μM DnaK, 1.15-μM DnaJ,
0.57-μM GrpE, 1.72-μM ClpB (hexamer)). Then, 17 μl of a
chaperone solution was mixed with 1 μl of DBeQ in DMSO or
pure DMSO as a control and preincubated for 10 min at 25 C.
Next, 1 μl of the heat-denatured luciferase (0.7 μM) and 1 μl of
ATP (100 mM) were added to the samples, followed by in-
cubation for 20 min at 25 C. To determine the luciferase
activity, 5 μl of each sample was transferred into 100 μl of the
luciferase substrate (Promega), previously dispensed into a
white 96-well plate. Luminescence was measured using Syn-
ergy H1 plate reader (BioTek, Winooski, VT).
Surface plasmon resonance
ClpB, DnaK, and the NBD of DnaK were extensively dia-
lyzed against the SPR buffer (20-mM Hepes, pH 7.4, 150-mM
NaCl, 20-mM MgCl2, 1-mM EDTA, 1-mM DTT). After dial-
ysis, the protein concentration was determined by the Bradford
method. The DBeQ–protein interactions were studied using a
Biacore T200 instrument (GE Healthcare) at 25 C. The pro-
teins were diluted to 300 μg/ml in 10-mM sodium acetate
buffer (pH 5 for ClpB DnaK or pH 4 for NBD) and immobi-
lized on HC1500M sensor chips (Xantec) by standard amine
Chemical modulation of ClpB–DnaKcoupling chemistry as described previously (70). A reference
flow cell was created by ethyl(dimethylaminopropyl) carbo-
diimide/N-hydroxysuccinimide activation followed by
quenching with 1 M ethanolamine (pH 9.0). Solvent correction
curves were obtained at the beginning and end and after every
50 injection cycles by injecting varying DMSO concentrations
(4.0, 4.4, 4.6, 4.8, 5.0, 5.2, 5.4, and 5.9% [v/v]). All experiments
were performed using a flow rate of 30 μl/min.
Binding isotherms were obtained with the ligand diluted to
different concentrations in the SPR running buffer HBSMTD
(20-mM Hepes, pH 7.4, 140-mM NaCl, 20-mM MgCl2, 5% (v/
v) DMSO, 0.005% (v/v) Tween-20). Replicate injections were
performed for all samples, and a buffer-only injection was
performed for every 12 injection cycles. To test the structural
integrity of ClpB after immobilization on the sensor chips, we
performed control titrations with ATPγS and adenosine. The
dissociation constants determined from those experiments
were 20 μM for ATPγS and 2 mM for adenosine. These
preliminary experiments indicated that the immobilization on
the SPR chip preserved the oligomeric structure of ClpB
because monomeric ClpB has low affinity toward ATP (Kd > 1
mM (62)). Moreover, the immobilized ClpB discriminated
between a nucleotide analog and a nucleoside, which indicated
an adequate structural integrity of ClpB on the sensor chips.
The resulting sensorgrams were analyzed using Biacore
T200 Evaluation Software v3.0 according to the following
procedure. Solvent correction curves were generated and
applied to all data sets, and all sensorgrams were double-
referenced by subtracting the most recent buffer blank injec-
tion. The signal immediately before injection stop of these
corrected sensorgrams was treated as the binding response.
GraphPad Prism was used for nonlinear least-squares fitting of
the model assuming either noncooperative or cooperative
binding of DBeQ to DnaK and ClpB, respectively.
Bacterial viability
E. coli MC4100, MC4100ΔclpB, dnaK103, and dnaK756
strains were used to determine an influence of DBeQ on
bacterial growth and viability. Bacteria were maintained in the
LB media, and in the case of the MC4100ΔclpB strain, LB was
supplemented with 30 μg/ml kanamycin. All experiments were
initiated by preparing overnight cultures inoculated from
single colonies and grown at 37 C. The dnaK103 and
dnaK756 overnight cultures were grown at 30 C. On the
following day, the cultures were diluted 100-fold in 10 ml of
LB without antibiotics and incubated at 37 C. The culture
optical density was monitored at 600 nm. When absorbance at
600 nm reached 0.4, the culture was divided into 1-ml aliquots
and supplemented with 10 μl of DMSO or different concen-
trations of DBeQ in DMSO. The samples were immediately
transferred into an incubator/shaker at temperature 37, 45, or
50 C. Bacteria were cultured for up to 4 h with shaking (200
RPM). At specific time points, 100 μl of each culture was
withdrawn and serially diluted in sterile 0.9% NaCl up to 106-
fold dilution. To estimate the number of viable cells, 5 μl or 10
μl of the diluted cultures was spread on the LB-agar plate
without an antibiotic. After a complete adsorption of liquid onthe LB-agar surface, the plates were incubated overnight at
37 C. On the following day, the bacterial colonies were
counted and the colony-forming units/ml were calculated.
Chemical library screening
An absorbance-based assay for ClpB ATPase activity was
developed by using BioMol Green Reagent (Enzo Life Sciences,
Farmington, NY) for screening in a 384-microplate–based
format. The optimized assay conditions were as follows: ClpB
(150 nM), ATP (200 mM), and κ-casein (25 μM) in 100-mM
Tris/HCl, pH 8, 10-mM MgCl2, 1-mM DTT, and 1-mM
EDTA. The samples were incubated for 10 min at 37 C,
and the ATP hydrolysis reaction was terminated by adding 80
μl of BIOMOL Green. Absorbance at 620 nm was measured
with a PerkinElmer EnSpire. The optimized assay was used to
screen compounds drawn from Selleck Bioactive library (1900
compounds; Selleck Chemicals, Houston, TX) in the presence
or absence of κ-casein.
Analytical ultracentrifugation
Protein samples (0.5 ml) of wt ClpB and its variants W462F
andW543F were dialyzed against 3 changes of 1 l of buffer AUC
(50-mMTris-HCl, pH 7.4, 200-mMKCl, 20-mMMgCl2, 1-mM
EDTA, 0.5-mM TCEP). After dialysis, the samples were
centrifuged (15 min, 13,000 RPM, 4 C). The supernatants were
collected, and the protein concentration was determined with
the Bradford assay. Sedimentation velocity experiments were
performed in Beckman Optima XL-I analytical ultracentrifuge
equipped with a 4-cell rotor and 2-sector cells. The ClpB sam-
ples were diluted to 1 mg/ml in the AUC buffer supplemented
with DMSO (5% (v/v) final concentration) with 1-mM ATPɤS,
with or without 50-μMDBeQ. Centrifugation was performed at
48,000 RPM at 20 C. The sedimentation profiles were collected
using the interference detection system and analyzed with the
Origin software supplied by the instrument manufacturer using
the time-derivative method of Stafford (71). Observed sedi-
mentation coefficients were corrected to values corresponding
to the density and viscosity of water (s20,w) using Sednterp
software (www.jphilo.mailway.com) with additional corrections
for the presence of 5% DMSO (72).
Fluorescence anisotropy
To monitor interactions between casein and ClpB, we used
FITC-casein and the substrate-trapping ClpB E279Q/E678Q
variant (52, 73). The titration of FITC-casein with ClpB
E279Q/E678Q in the presence of ATP or ADP and the fluo-
rescence anisotropy measurements were performed as previ-
ously described (65).
To monitor interactions between the peptide B2 and DnaK,
the DnaK stock was diluted in buffer C (50-mM Tris-HCl, pH
7.4, 20-mM MgCl2, 1-mM EDTA, 0.5-mM TCEP) to a final
concentration of 1 μM. DBeQ solutions in DMSO (20 μl)
were mixed with 372 μl of 1-μM DnaK. After 10 min of
incubation at room temperature, the samples were supple-
mented with 8 μl of 1-μM FITC-B2 in buffer C (FITC-Ahx-
QRKLFFNLRKTKQRLGWFNQ-NH2) (51). The FITC-B2J. Biol. Chem. (2021) 296 100079 11
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incubation at room temperature, fluorescence anisotropy of
FITC-B2 was measured with a PerkinElmer LS55 (λexc = 485
nm (slit: 15 nm), λem = 521 (slit: 20 nm)).
Western blotting
The ClpB protein level in E. coli cells was analyzed by
Western blotting. Overnight culture of each strain was diluted
100-fold and incubated at 37 C with shaking (200 RPM).
When the absorbance at 600 nm reached 0.4, the culture was
split into two: for one, the incubation at 37 C continued, while
the second one was transferred to 45 C. After 2 h of incu-
bation at the target temperatures, the cells were collected by
centrifugation. The supernatant was discarded, and cell pellets
were suspended in 160 μl of 2x Laemmli sample buffer. Sixty
microliters of each sample was resolved in duplicates in 8%
SDS-PAGE gel. The gel was cut into two parts, one part was
used for blotting onto a nitrocellulose membrane and the
second part of gel was stained in Coomassie R-250. The
membrane was blocked with 5% nonfat dried milk dissolved in
TBST buffer (19-mM Tris-HCl, pH 7.4, 137-mM NaCl, 2.7-
mM KCl, 0.2% Tween-20) overnight at 4 C. Next, the mem-
brane was incubated with rabbit polyclonal anti-ClpB IgG
(1:50,000 in milk) for 1 h at room temperature. After incu-
bation with the primary antibody, the membrane was washed
in TBST buffer (4 times, 10 min). Next, the membrane was
incubated with anti-rabbit horseradish peroxidase-conjugated
secondary antibodies for 1 h at room temperature and washed
in TBST (4 times, 10 min) and then TBST without Tween-20
(10 min). Signal detection was performed using SuperSignal
West Pico Chemiluminescent Substrate (Pierce) and an Azure
c500 digital imaging system (Azure Biosystems, Dublin, CA).
Confocal microscopy
ClpB-YFP and Luciferase-YFP were expressed at low levels
in E. coli strains ΔclpB, dnaK103, and dnaK756 as described
before (44). The expression of ClpB-YFP and YFP-Luciferase
was initiated by addition of 200-μM IPTG or 0.02% (w/v)
arabinose, respectively. The bacterial cells were cultured at 30
C with 100-μMDBeQ or DMSO only. Protein translation was
stopped by addition of erythromycin (30 μg/ml), and each
culture was divided into two samples. One sample remained at
30 C (control), whereas the other sample was transferred to
45 C for 30 min (heat-shock conditions).
A thin layer of 1% agarose (TopVision Low Melting Point
Agarose, Thermo Scientific) was prepared on a clean micro-
scope glass slide. A small drop of 1% agarose was placed near
the frosted end of the glass slide while bringing a second glass
slide at a 30 to 45 angle from above, allowing the agarose drop
to spread along the contact edge. The top slide was moved
gently across the bottom slide to produce an evenly spread
thin layer of agarose. An E. coli culture sample (1 μl) was
immediately placed on the agarose-covered glass slide, covered
with a cover slip, and used for fluorescence imaging.
Fluorescence imaging was performed using a Carl Zeiss
LSM 880 Airyscan confocal microscope equipped with a Plan-12 J. Biol. Chem. (2021) 296 100079Apochromat 63x/1.40 Oil DIC M27 objective coupled with a
YFP Filter (excitation at 514 nm, emission at 561 nm, laser
strength 0.98%). Zen 2.3 lite software was used for image
capture and processing.
Data availability
All relevant data are available within this manuscript and
the associated Supporting Information.
Acknowledgments—The authors thank Bernd Bukau, Axel Mogk,
Sabina Kedzierska-Mieszkowska, and Francois Baneyx for kindly
providing the reagents and Joel Sanneman from the Kansas State
University Confocal Microscopy and Microfluorometry Core for
help with confocal microscopy imaging.
Author contributions—M. Z. and F. J. S. conceptualization, P. G.,
C. B. R., S. S., A. R., and B. V. G. investigation; P. G., C. B. R., S. S.,
A. R., B. V. G., and M.Z. data analysis; M.Z. writing-original
manuscript draft; P. G., C. B. R., S. S., A. R., B. V. G., F. J. S., and
M.Z. writing-manuscript review and editing.
Funding and additional information—This study was supported by
grants from the National Institutes of Health, AI121366 and
AI141586 (to M. Z.) and GM121511 (to B. V. G.), and by the Kansas
Agricultural Experiment Station (contribution 19-063-J). The con-
tent is solely the responsibility of the authors and does not neces-
sarily represent the official views of the National Institutes of
Health.
Conflict of interest—The authors declare that they have no conflicts
of interest with the contents of this article.
Abbreviations—The abbreviations used are: DBeQ, N2,N4-
dibenzylquinazoline-2,4-diamine; DMSO, dimethyl sulfoxide;
G6PDH, glucose-6-phosphate dehydrogenase; Hsps, heat-shock
proteins; KJE, DnaK–DnaJ–GrpE; NBD, nucleotide-binding
domain; SPR, surface plasmon resonance; TCEP, tris(2-carbox-
yethyl)phosphine.
References
1. Stewart, G. R., and Young, D. B. (2004) Heat-shock proteins and the host-
pathogen interaction during bacterial infection. Curr. Opin. Immunol. 16,
506–510
2. Henderson, B., Allan, E., and Coates, A. R. (2006) Stress wars: the direct
role of host and bacterial molecular chaperones in bacterial infection.
Infect. Immun. 74, 3693–3706
3. Neckers, L., and Tatu, U. (2008) Molecular chaperones in pathogen
virulence: emerging new targets for therapy. Cell Host Microbe. 4,
519–527
4. Zolkiewski, M., Zhang, T., and Nagy, M. (2012) Aggregate reactivation
mediated by the Hsp100 chaperones. Arch. Biochem. Biophys. 520, 1–6
5. Erives, A. J., and Fassler, J. S. (2015) Metabolic and chaperone gene loss
marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones
sharing mitochondrial enzymes as clients. PLoS One 10, e0117192
6. Glover, J. R., and Lindquist, S. (1998) Hsp104, Hsp70, and Hsp40: a novel
chaperone system that rescues previously aggregated proteins. Cell 94,
73–82
7. Zolkiewski, M. (1999) ClpB cooperates with DnaK, DnaJ, and GrpE in
suppressing protein aggregation. A novel multi-chaperone system from
Escherichia coli. J. Biol. Chem. 274, 28083–28086
Chemical modulation of ClpB–DnaK8. Goloubinoff, P., Mogk, A., Zvi, A. P., Tomoyasu, T., and Bukau, B. (1999)
Sequential mechanism of solubilization and refolding of stable protein
aggregates by a bichaperone network. Proc. Natl. Acad. Sci. U. S. A. 96,
13732–13737
9. de Oliveira, N. E., Abranches, J., Gaca, A. O., Laport, M. S., Damaso, C. R.,
Bastos Mdo, C., Lemos, J. A., and Giambiagi-deMarval, M. (2011) clpB, a
class III heat-shock gene regulated by CtsR, is involved in thermotol-
erance and virulence of Enterococcus faecalis.Microbiology 157, 656–665
10. Frees, D., Chastanet, A., Qazi, S., Sorensen, K., Hill, P., Msadek, T., and
Ingmer, H. (2004) Clp ATPases are required for stress tolerance, intra-
cellular replication and biofilm formation in Staphylococcus aureus. Mol.
Microbiol. 54, 1445–1462
11. Lehoux, D. E., Sanschagrin, F., and Levesque, R. C. (2002) Identification of
in vivo essential genes from Pseudomonas aeruginosa by PCR-based
signature-tagged mutagenesis. FEMS Microbiol. Lett. 210, 73–80
12. Estorninho, M., Smith, H., Thole, J., Harders-Westerveen, J., Kierzek, A.,
Butler, R. E., Neyrolles, O., and Stewart, G. R. (2010) ClgR regulation
of chaperone and protease systems is essential for Mycobacterium
tuberculosis parasitism of the macrophage. Microbiology 156, 3445–3455
13. Vaubourgeix, J., Lin, G., Dhar, N., Chenouard, N., Jiang, X., Botella, H.,
Lupoli, T., Mariani, O., Yang, G., Ouerfelli, O., Unser, M., Schnappinger,
D., McKinney, J., and Nathan, C. (2015) Stressed mycobacteria use the
chaperone ClpB to sequester irreversibly oxidized proteins asymmetri-
cally within and between cells. Cell Host Microbe. 17, 178–190
14. Kannan, T. R., Musatovova, O., Gowda, P., and Baseman, J. B. (2008)
Characterization of a unique ClpB protein of Mycoplasma pneumoniae
and its impact on growth. Infect. Immun. 76, 5082–5092
15. Turner, A. K., Lovell, M. A., Hulme, S. D., Zhang-Barber, L., and Barrow,
P. A. (1998) Identification of Salmonella typhimurium genes required for
colonization of the chicken alimentary tract and for virulence in newly
hatched chicks. Infect. Immun. 66, 2099–2106
16. Pieper, R., Zhang, Q., Parmar, P. P., Huang, S. T., Clark, D. J., Alami, H.,
Donohue-Rolfe, A., Fleischmann, R. D., Peterson, S. N., and Tzipori, S.
(2009) The Shigella dysenteriae serotype 1 proteome, profiled in the host
intestinal environment, reveals major metabolic modifications and
increased expression of invasive proteins. Proteomics. 9, 5029–5045
17. Kuntumalla, S., Zhang, Q., Braisted, J. C., Fleischmann, R. D., Peterson, S.
N., Donohue-Rolfe, A., Tzipori, S., and Pieper, R. (2011) In vivo versus
in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals
changes in the expression of proteins involved in virulence, stress and
energy metabolism. BMC Microbiol. 11, 147
18. Capestany, C. A., Tribble, G. D., Maeda, K., Demuth, D. R., and Lamont,
R. J. (2008) Role of the Clp system in stress tolerance, biofilm formation,
and intracellular invasion in Porphyromonas gingivalis. J. Bacteriol. 190,
1436–1446
19. Meibom, K. L., Dubail, I., Dupuis, M., Barel, M., Lenco, J., Stulik, J.,
Golovliov, I., Sjostedt, A., and Charbit, A. (2008) The heat-shock protein
ClpB of Francisella tularensis is involved in stress tolerance and is
required for multiplication in target organs of infected mice. Mol.
Microbiol. 67, 1384–1401
20. Lourdault, K., Cerqueira,G.M.,Wunder, E.A., Jr., andPicardeau,M. (2011)
Inactivation of clpB in the pathogen Leptospira interrogans reduces viru-
lence and resistance to stress conditions. Infect. Immun. 79, 3711–3717
21. Krobitsch, S., and Clos, J. (1999) A novel role for 100 kD heat shock
proteins in the parasite Leishmania donovani. Cell Stress Chaperones. 4,
191–198
22. Zhang, T., Kedzierska-Mieszkowska, S., Liu, H., Cheng, C., Ganta, R. R.,
and Zolkiewski, M. (2013) Aggregate-reactivation activity of the molec-
ular chaperone ClpB from Ehrlichia chaffeensis. PLoS One 8, e62454
23. Kuczynska-Wisnik, D., Cheng, C., Ganta, R. R., and Zolkiewski, M. (2017)
Protein aggregation in Ehrlichia chaffeensis during infection of
mammalian cells. FEMS Microbiol. Lett 364, fnx059
24. Kalanon, M., and McFadden, G. I. (2010) Malaria, Plasmodium falcipa-
rum and its apicoplast. Biochem. Soc. Trans. 38, 775–782
25. Ngansop, F., Li, H., Zolkiewska, A., and Zolkiewski, M. (2013)
Biochemical characterization of the apicoplast-targeted AAA+ ATPase
ClpB from Plasmodium falciparum. Biochem. Biophys. Res. Commun. 439,
191–19526. de Koning-Ward, T. F., Gilson, P. R., Boddey, J. A., Rug, M., Smith, B. J.,
Papenfuss, A. T., Sanders, P. R., Lundie, R. J., Maier, A. G., Cowman, A. F.,
and Crabb, B. S. (2009) A newly discovered protein export machine in
malaria parasites. Nature 459, 945–949
27. Beck, J. R., Muralidharan, V., Oksman, A., and Goldberg, D. E. (2014)
PTEX component HSP101 mediates export of diverse malaria effectors
into host erythrocytes. Nature 511, 592–595
28. Neuwald, A. F., Aravind, L., Spouge, J. L., and Koonin, E. V. (1999) AAA+:
a class of chaperone-like ATPases associated with the assembly, opera-
tion, and disassembly of protein complexes. Genome Res. 9, 27–43
29. Hanson, P. I., and Whiteheart, S. W. (2005) AAA+ proteins: have engine,
will work. Nat. Rev. Mol. Cell Biol. 6, 519–529
30. Weibezahn, J., Tessarz, P., Schlieker, C., Zahn, R., Maglica, Z., Lee, S.,
Zentgraf, H., Weber-Ban, E. U., Dougan, D. A., Tsai, F. T., Mogk, A., and
Bukau, B. (2004) Thermotolerance requires refolding of aggregated pro-
teins by substrate translocation through the central pore of ClpB. Cell
119, 653–665
31. Avellaneda, M. J., Franke, K. B., Sunderlikova, V., Bukau, B., Mogk, A.,
and Tans, S. J. (2020) Processive extrusion of polypeptide loops by a
Hsp100 disaggregase. Nature 578, 317–320
32. Chou, T. F., Brown, S. J., Minond, D., Nordin, B. E., Li, K., Jones, A. C.,
Chase, P., Porubsky, P. R., Stoltz, B. M., Schoenen, F. J., Patricelli, M. P.,
Hodder, P., Rosen, H., and Deshaies, R. J. (2011) Reversible inhibitor of
p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein
clearance pathways. Proc. Natl. Acad. Sci. U. S. A. 108, 4834–4839
33. Anderson, D. J., Le Moigne, R., Djakovic, S., Kumar, B., Rice, J., Wong, S.,
Wang, J., Yao, B., Valle, E., Kiss von Soly, S., Madriaga, A., Soriano, F.,
Menon, M. K., Wu, Z. Y., Kampmann, M., et al. (2015) Targeting the
AAA ATPase p97 as an approach to treat cancer through disruption of
protein homeostasis. Cancer Cell 28, 653–665
34. Vekaria, P. H., Home, T., Weir, S., Schoenen, F. J., and Rao, R. (2016)
Targeting p97 to disrupt protein homeostasis in cancer. Front. Oncol. 6,
181
35. Chou, T. F., Li, K., Frankowski, K. J., Schoenen, F. J., and Deshaies, R. J.
(2013) Structure-activity relationship study reveals ML240 and ML241 as
potent and selective inhibitors of p97 ATPase. ChemMedChem. 8,
297–312
36. Magnaghi, P., D’Alessio, R., Valsasina, B., Avanzi, N., Rizzi, S., Asa, D.,
Gasparri, F., Cozzi, L., Cucchi, U., Orrenius, C., Polucci, P., Ballinari, D.,
Perrera, C., Leone, A., Cervi, G., et al. (2013) Covalent and allosteric
inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem.
Biol. 9, 548–556
37. Martin, I., Underhaug, J., Celaya, G., Moro, F., Teigen, K., Martinez, A.,
and Muga, A. (2013) Screening and evaluation of small organic molecules
as ClpB inhibitors and potential antimicrobials. J. Med. Chem. 56,
7177–7189
38. Akoev, V., Gogol, E. P., Barnett, M. E., and Zolkiewski, M. (2004)
Nucleotide-induced switch in oligomerization of the AAA+ ATPase
ClpB. Protein Sci. 13, 567–574
39. Swain, J. F., Dinler, G., Sivendran, R., Montgomery, D. L., Stotz, M., and
Gierasch, L. M. (2007) Hsp70 chaperone ligands control domain associ-
ation via an allosteric mechanism mediated by the interdomain linker.
Mol. Cell 26, 27–39
40. Squires, C. L., Pedersen, S., Ross, B. M., and Squires, C. (1991) ClpB is the
Escherichia coli heat shock protein F84.1. J. Bacteriol 173, 4254–4262
41. Spence, J., Cegielska, A., and Georgopoulos, C. (1990) Role of Escherichia
coli heat shock proteins DnaK and HtpG (C62.5) in response to nutri-
tional deprivation. J. Bacteriol. 172, 7157–7166
42. Winkler, J., Tyedmers, J., Bukau, B., and Mogk, A. (2012) Hsp70 targets
Hsp100 chaperones to substrates for protein disaggregation and prion
fragmentation. J. Cell Biol. 198, 387–404
43. Buchberger, A., Gassler, C. S., Buttner, M., McMacken, R., and Bukau, B.
(1999) Functional defects of the DnaK756 mutant chaperone of Escher-
ichia coli indicate distinct roles for amino- and carboxyl-terminal residues
in substrate and co-chaperone interaction and interdomain communi-
cation. J. Biol. Chem. 274, 38017–38026
44. Winkler, J., Seybert, A., Konig, L., Pruggnaller, S., Haselmann, U., Sourjik,
V., Weiss, M., Frangakis, A. S., Mogk, A., and Bukau, B. (2010)J. Biol. Chem. (2021) 296 100079 13
Chemical modulation of ClpB–DnaKQuantitative and spatio-temporal features of protein aggregation in
Escherichia coli and consequences on protein quality control and cellular
ageing. EMBO J. 29, 910–923
45. Chapman, E., Maksim, N., de la Cruz, F., and La Clair, J. J. (2015) In-
hibitors of the AAA+ chaperone p97. Molecules. 20, 3027–3049
46. DeGraw, J. I., Brown, V. H., and Colwell, W. T. (1974) Potential anti-
leprotic agents. 3. Inhibition of mycobacterial dihydrofolic reductase
by 2,4-diamino-5-methyl-6-alkylquinazolines. J. Med. Chem. 17,
762–764
47. Van Horn, K. S., Burda, W. N., Fleeman, R., Shaw, L. N., and Manetsch, R.
(2014) Antibacterial activity of a series of N2,N4-disubstituted quinazo-
line-2,4-diamines. J. Med. Chem. 57, 3075–3093
48. Harbut, M. B., Patel, B. A., Yeung, B. K., McNamara, C. W., Bright, A. T.,
Ballard, J., Supek, F., Golde, T. E., Winzeler, E. A., Diagana, T. T., and
Greenbaum, D. C. (2012) Targeting the ERAD pathway via inhibition of
signal peptide peptidase for antiparasitic therapeutic design. Proc. Natl.
Acad. Sci. U. S. A. 109, 21486–21491
49. Van Horn, K. S., Zhu, X., Pandharkar, T., Yang, S., Vesely, B., Vanaer-
schot, M., Dujardin, J. C., Rijal, S., Kyle, D. E., Wang, M. Z., Werbovetz,
K. A., and Manetsch, R. (2014) Antileishmanial activity of a series of N(2),
N(4)-disubstituted quinazoline-2,4-diamines. J. Med. Chem. 57,
5141–5156
50. Hoskins, J. R., Doyle, S. M., and Wickner, S. (2009) Coupling ATP uti-
lization to protein remodeling by ClpB, a hexameric AAA+ protein. Proc.
Natl. Acad. Sci. U. S. A. 106, 22233–22238
51. Schlieker, C., Weibezahn, J., Patzelt, H., Tessarz, P., Strub, C., Zeth, K.,
Erbse, A., Schneider-Mergener, J., Chin, J. W., Schultz, P. G., Bukau, B.,
and Mogk, A. (2004) Substrate recognition by the AAA+ chaperone ClpB.
Nat. Struct. Mol. Biol. 11, 607–615
52. Barnett, M. E., Nagy, M., Kedzierska, S., and Zolkiewski, M. (2005) The
amino-terminal domain of ClpB supports binding to strongly aggregated
proteins. J. Biol. Chem. 280, 34940–34945
53. Rizo, A. N., Lin, J., Gates, S. N., Tse, E., Bart, S. M., Castellano, L. M.,
DiMaio, F., Shorter, J., and Southworth, D. R. (2019) Structural basis for
substrate gripping and translocation by the ClpB AAA+ disaggregase.
Nat. Commun. 10, 2393
54. Haslberger, T., Weibezahn, J., Zahn, R., Lee, S., Tsai, F. T., Bukau, B., and
Mogk, A. (2007) M domains couple the ClpB threading motor with the
DnaK chaperone activity. Mol. Cell 25, 247–260
55. Oguchi, Y., Kummer, E., Seyffer, F., Berynskyy, M., Anstett, B., Zahn, R.,
Wade, R. C., Mogk, A., and Bukau, B. (2012) A tightly regulated mo-
lecular toggle controls AAA+ disaggregase. Nat. Struct. Mol. Biol. 19,
1338–1346
56. Sen, M., Maillard, R. A., Nyquist, K., Rodriguez-Aliaga, P., Presse, S.,
Martin, A., and Bustamante, C. (2013) The ClpXP protease unfolds sub-
strates using a constant rate of pulling but different gears.Cell155, 636–646
57. Rodriguez-Aliaga, P., Ramirez, L., Kim, F., Bustamante, C., and Martin, A.
(2016) Substrate-translocating loops regulate mechanochemical coupling
and power production in AAA+ protease ClpXP. Nat. Struct. Mol. Biol.
23, 974–981
58. Jones, A. M., Westwood, I. M., Osborne, J. D., Matthews, T. P.,
Cheeseman, M. D., Rowlands, M. G., Jeganathan, F., Burke, R., Lee, D.,
Kadi, N., Liu, M., Richards, M., McAndrew, C., Yahya, N., Dobson, S. E.,14 J. Biol. Chem. (2021) 296 100079et al. (2016) A fragment-based approach applied to a highly flexible
target: insights and challenges towards the inhibition of HSP70 isoforms.
Sci. Rep. 6, 34701
59. Lipinska, N., Zietkiewicz, S., Sobczak, A., Jurczyk, A., Potocki, W.,
Morawiec, E., Wawrzycka, A., Gumowski, K., Slusarz, M., Rodziewicz-
Motowidlo, S., Chrusciel, E., and Liberek, K. (2013) Disruption of ionic
interactions between the nucleotide binding domain 1 (NBD1) and
middle (M) domain in Hsp100 disaggregase unleashes toxic hyperactivity
and partial independence from Hsp70. J. Biol. Chem. 288, 2857–2869
60. Chamera, T., Klosowska, A., Janta, A., Wyszkowski, H., Obuchowski, I.,
Gumowski, K., and Liberek, K. (2019) Selective hsp70-dependent docking
of Hsp104 to protein aggregates protects the cell from the toxicity of the
disaggregase. J. Mol. Biol. 431, 2180–2196
61. Guzman, L. M., Belin, D., Carson, M. J., and Beckwith, J. (1995) Tight
regulation, modulation, and high-level expression by vectors containing
the arabinose PBAD promoter. J. Bacteriol. 177, 4121–4130
62. Barnett, M. E., Zolkiewska, A., and Zolkiewski, M. (2000) Structure and
activity of ClpB from Escherichia coli. Role of the amino-and -carboxyl-
terminal domains. J. Biol. Chem. 275, 37565–37571
63. Nagy, M., Akoev, V., and Zolkiewski, M. (2006) Domain stability in the
AAA+ ATPase ClpB from Escherichia coli. Arch. Biochem. Biophys. 453,
63–69
64. Zhang, T., Ploetz, E. A., Nagy, M., Doyle, S. M., Wickner, S., Smith, P. E.,
and Zolkiewski, M. (2012) Flexible connection of the N-terminal domain
in ClpB modulates substrate binding and the aggregate reactivation effi-
ciency. Proteins 80, 2758–2768
65. Ranaweera, C. B., Glaza, P., Yang, T., and Zolkiewski, M. (2018) Inter-
action of substrate-mimicking peptides with the AAA+ ATPase ClpB
from Escherichia coli. Arch. Biochem. Biophys. 655, 12–17
66. Georgopoulos, C. P. (1977) A new bacterial gene (groPC) which affects
lambda DNA replication. Mol. Gen. Genet 151, 35–39
67. Hess, H. H., and Derr, J. E. (1975) Assay of inorganic and organic
phosphorus in the 0.1-5 nanomole range. Anal. Biochem 63, 607–613
68. Lanzetta, P. A., Alvarez, L. J., Reinach, P. S., and Candia, O. A. (1979) An
improved assay for nanomole amounts of inorganic phosphate. Anal.
Biochem. 100, 95–97
69. Diamant, S., Ben-Zvi, A. P., Bukau, B., and Goloubinoff, P. (2000) Size-
dependent disaggregation of stable protein aggregates by the DnaK
chaperone machinery. J. Biol. Chem. 275, 21107–21113
70. Garcia, B. L., Skaff, D. A., Chatterjee, A., Hanning, A., Walker, J. K.,
Wyckoff, G. J., and Geisbrecht, B. V. (2017) Identification of C3b-binding
small-molecule complement inhibitors using cheminformatics. J. Immu-
nol. 198, 3705–3718
71. Stafford, W. F., 3rd (1992) Boundary analysis in sedimentation transport
experiments: a procedure for obtaining sedimentation coefficient distri-
butions using the time derivative of the concentration profile. Anal.
Biochem. 203, 295–301
72. LeBel, R. G., and Goring, D. A. I. (1962) Density, viscosity, refractive
index, and hygroscopicity of mixtures of water and dimethyl sulfoxide. J.
Chem. Eng. Data 7, 100–101
73. Weibezahn, J., Schlieker, C., Bukau, B., and Mogk, A. (2003) Character-
ization of a trap mutant of the AAA+ chaperone ClpB. J. Biol. Chem. 278,
32608–32617
